About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Austin | 116 Studies

Clinical Trials Ovarian CancerAustin

Ovarian Cancer Clinical Trials in Austin

Find 116 clinical trials for ovarian cancer near Austin, Texas. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Austin

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 101-116 of 116 trials

CompletedA Study LY2228820 for Recurrent Ovarian CancerA study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.NCT01663857·Phoenix, Arizona and 29 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerGLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants…NCT05445778·Mobile, Alabama and 263 others

Active not recruitingTesting the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneThis phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating…NCT03660826·Birmingham, Alabama and 760 others

CompletedA Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesThis is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity…NCT03719326·Scottsdale, Arizona and 26 others

CompletedCollecting Tumor Samples From Patients With Gynecological TumorsThis laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors.NCT00897442·Fayetteville, Arkansas and 186 others

TerminatedRandomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy ExistsThis study will examine the efficacy and safety of lapatinib in patients with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder…NCT00447226·Denver, Colorado and 19 others

TerminatedStudy of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesA first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignanciesNCT06052852·Palo Alto, California and 5 others

CompletedStudy of Cabozantinib (XL184) in Adults With Advanced MalignanciesThis is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.NCT00940225·Scottsdale, Arizona and 46 others

RecruitingA Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.NCT07776691·Washington D.C., District of Columbia and 12 others

RecruitingA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesCancer is a condition where cells in a specific part of body grow and reproduce uncontrollably.NCT07024784·Los Angeles, California and 20 others

CompletedDose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) proﬁles of RMC-4630 and cobimetinib in adult participants with…NCT03989115·Scottsdale, Arizona and 23 others

Active not recruitingRelacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerThe primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated…NCT05257408·Phoenix, Arizona and 115 others

TerminatedNUC-1031 in Patients With Platinum-Resistant Ovarian CancerThis study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer.NCT03146663·Phoenix, Arizona and 16 others

CompletedA Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensThis is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy…NCT02354586·Chandler, Arizona and 54 others

RecruitingStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionThe purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1…NCT07214779·Anchorage, Alaska and 197 others

RecruitingA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsThis is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.NCT05914116·Tucson, Arizona and 106 others

PreviousPage 6 of 6

Other Conditions in Austin

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia